Literature DB >> 1241159

Antimitotic activity of the potent tumor inhibitor maytansine.

S Remillard, L I Rebhun, G A Howie, S M Kupchan.   

Abstract

Maytansine, at 6x10(-8)M, irreversibly inhibits cell division in eggs of sea urchins and clams. It causes the disappearance of a mitotic apparatus or prevents one from forming if added at early stages. Maytansine does not affect formation of the mitotic organizing center but does inhibit in vitro polymerization of tubulin. Maytansine and vincristine inhibit in vitro polymerization of tubulin at about the same concentrations, but vincristine is about 100 times less effective as an inhibitor of cleavage in marine eggs.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1241159     DOI: 10.1126/science.1241159

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  56 in total

1.  High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.

Authors:  Jonathan N Thon; Matthew T Devine; Antonija Jurak Begonja; Jay Tibbitts; Joseph E Italiano
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Authors:  Simona Lapusan; Maria B Vidriales; Xavier Thomas; Stephane de Botton; Anne Vekhoff; Ruoping Tang; Charles Dumontet; Rodica Morariu-Zamfir; John M Lambert; Marie-Laure Ozoux; Philippe Poncelet; Jesus F San Miguel; Ollivier Legrand; Daniel J DeAngelo; Francis J Giles; Jean-Pierre Marie
Journal:  Invest New Drugs       Date:  2011-04-26       Impact factor: 3.850

Review 3.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

Authors:  David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

Review 4.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

Review 5.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

Review 6.  Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.

Authors:  Ricardo L B Costa; Brian J Czerniecki
Journal:  NPJ Breast Cancer       Date:  2020-03-12

Review 7.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

Review 8.  Recent advances and novel treatment paradigms in acute lymphocytic leukemia.

Authors:  Nikolaos Papadantonakis; Anjali S Advani
Journal:  Ther Adv Hematol       Date:  2016-06-29

9.  The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Authors:  Hernan Carol; Barbara Szymanska; Kathryn Evans; Ingrid Boehm; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2013-02-20       Impact factor: 12.531

10.  P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.

Authors:  Ruoping Tang; Simy Cohen; Jean-Yves Perrot; Anne-Marie Faussat; Claudia Zuany-Amorim; Zora Marjanovic; Hamid Morjani; Fanny Fava; Elise Corre; Ollivier Legrand; Jean-Pierre Marie
Journal:  BMC Cancer       Date:  2009-06-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.